HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) View Online Only Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (24) Citing Articles via Google Scholar Google Scholar Articles by Vicari, R. M. Search for Related Content PubMed PubMed Citation Articles by Vicari, R. M.

Efficacy and Safety of Fasudil in Patients With Stable Angina

A Double-Blind, Placebo-Controlled, Phase 2 Trial

Ralph M. Vicari, MD, FACC^_*,_*, Bernard Chaitman, MD, FACC, Deborah Keefe, MD, MPH, FACC, William B. Smith, MD, FACC, Steven G. Chrysant, MD, PhD, FACC^||, Melvin J. Tonkon, MD, FACC^¶, Neville Bittar, MD, FACC^#, Robert J. Weiss, MD, FACC^_**, Hugo Morales-Ballejo, MD, FACC, Udho Thadani, MBBS, MRCP, FRCPC, FACC for the Fasudil Study Group

^_* MIMA Century Research Associates, Melbourne, Florida
St. Louis University, St. Louis, Missouri
Berlex, Inc., Montville, New Jersey
New Orleans Center for Clinical Research, New Orleans, Louisiana
^|| Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma
^¶ Apex Research Institute, Santa Ana, California
^# Gemini Scientific, Madison, Wisconsin
^_** Androscoggin Cardiology Associates, Auburn, Maine
VA Medical Center, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma

View larger version (10K): [in a new window]   Figure 1 Schematic diagram of the study design. Exercise testing (X) was performed before dosing (trough), 1 h after dosing (peak), and 4 h after dosing of both fasudil and matching placebo tablets. tid = three times daily.

View larger version (27K): [in a new window]   Figure 2 Patient disposition during the study.

View larger version (22K): [in a new window]   Figure 3 Changes in exercise treadmill testing duration from baseline at peak for fasudil- (solid bars) and placebo-treated (open bars) patients (mean ± standard deviation). tid = three times daily.

View larger version (20K): [in a new window]   Figure 4 Changes in mean time to 1 mm ST-segment depression from baseline for fasudil- (solid bars) and placebo-treated (open bars) patients. *p = 0.001. tid = three times daily.

View larger version (18K): [in a new window]   Figure 5 Improvements in angina by 1 Canadian Cardiovascular Society angina class in patients treated with fasudil (solid bars) and placebo (open bars). tid = three times daily.

View larger version (18K): [in a new window]   Figure 6 Improvement in Seattle Angina Questionnaire score. (A) Physical limitation scale. (B) Treatment satisfaction scale. *p < 0.05. tid = three times daily. Open bars = placebo; solid bars = fasudil.